Master Rollover Protocol for Continued Safety Assessment of Study Drug
- Conditions
- Cancer
- Registration Number
- NCT02632994
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- To be eligible patients must be currently receiving benefit in a concluded Lilly study for a compound that has opened an addendum in the continued access protocol.
Read More
Exclusion Criteria
- Patients must not be concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
Read More
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
Sarah Cannon Cancer Center
🇺🇸Nashville, Tennessee, United States
UCLA Medical Center
🇺🇸Torrance, California, United States
Fort Wayne Oncology & Hematology
🇺🇸Fort Wayne, Indiana, United States